2024-11-06T06:25:15-06:00 2023-12-31 871353108 EISNER ADVISORY GROUP LLC 130 NORTH 18TH STREET SUITE 3000 PHILADELPHIA PA 191032757 990 2023-01-01 232213205 NATIONAL DISEASE RESEARCH INTERCHANGE NATI 2155577361 1601 CHERRY ST SUITE 1700 PHILADELPHIA PA 19102 WILLIAM LEINWEBER PRESIDENT 2155577361 2024-10-30 1 0 HELEN M MARTIN P01330899 2158818800 2023 2024-10-15 13:58:12Z WILLIAM LEINWEBER 1601 CHERRY ST SUITE 1700 PHILADELPHIA PA 19102 9146487 0 X WWW.NDRIRESOURCE.ORG X 1988 PA ADVANCING THE PROCUREMENT, PRESERVATION AND DISTRIBUTION OF HUMAN CELLS, TISSUES AND ORGANS FOR BIOMEDICAL RESEARCH, NATIONALLY AND INTERNATIONALLY. 16 15 41 15 0 0 3309348 4675847 4156336 4393163 15922 77477 -79091 0 7402515 9146487 0 0 0 0 3112794 3643246 0 0 0 5019862 5611626 8132656 9254872 -730141 -108385 6908115 7181811 4985355 5391136 1922760 1790675 THE MISSION OF NDRI IS TO PROVIDE HUMAN BIOSPECIMENS WORLDWIDE TO ADVANCE BIOMEDICAL/BIOSCIENCE RESEARCH AND DEVELOPMENT AND EDUCATION IN THE LIFE SCIENCES. 0 0 4363296 798747 HUMAN TISSUE AND RESOURCE FOR RESEARCH: NDRI RECEIVED A FEDERAL AWARD FOR THE HUMAN TISSUE AND ORGAN RESOURCE FOR THE PROCUREMENT AND DISTRIBUTION OF NORMAL AND DISEASED HUMAN ORGANS AND TISSUES TO ADVANCE BIOMEDICAL SCIENCE. 434668 2568060 PARTNER PROGRAM: COORDINATES VARIOUS HUMAN ORGAN AND TISSUE PROCUREMENT PROGRAMS WITH THE PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES TO ACCELERATE RESEARCH AND DEVELOPMENT. SEVERAL OF THESE PROGRAMS HAVE LED TO THE DEVELOPMENT OF TREATMENTS FOR MEDICAL CONDITIONS SUCH AS LUNG DISEASE, DIABETES, AND CANCER, TO NAME ONLY A FEW. OTHER PARTNER PROGRAMS HAVE LED TO THE CREATION OF RESEARCH TOOLS FOR USE IN NUMEROUS TOXICOLOGY AND DRUG DISCOVERY PLATFORMS. 1523947 1026356 RESEARCH COLLABORATIONS WITH FOUNDATION AND PATIENT ADVOCACY GROUPS (PAG): NDRI MAINTAINS COLLABORATIONS WITH A VARIETY OF DIFFERENT FOUNDATION AND PATIENT ADVOCACY GROUPS FOCUSED ON THE ADVANCEMENT OF RESEARCH IN EACH OF THEIR RESPECTIVE AREAS OF INTEREST. THESE COLLABORATIONS BRING TOGETHER PATIENTS, PAGS, FOUNDATIONS, NDRI AND THE PHARMACEUTICAL INDUSTRY TO HELP ADVANCE R&D UTILIZING CRITICAL HUMAN BIOSPECIMENS GIFTED BY PATIENTS/DONORS. 6321911 1 1 0 1 0 0 0 0 0 0 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 34 0 1 41 1 0 0 0 0 0 0 0 0 0 0 0 0 X 16 15 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 PA X X TOM MALECKI CFO VP ADMINISTRATION 2155577361 1601 CHERRY ST SUITE 1700 PHILADELPHIA PA 19102 WILLIAM LEINWEBER PRESIDENT & CEO 37.50 X X 407201 0 66400 MARY JC HENDRIX CHAIR OF THE BOARD 1.00 X X 0 0 0 DAVID M ALBERT BOARD MEMBER 1.00 X 0 0 0 SHAWN BLACKBURN BOARD MEMBER 1.00 X 0 0 0 SULAYMAN DIB-HAJJ BOARD MEMBER 1.00 X 0 0 0 MEGAN KASIMATIS SINGLETON BOARD MEMBER 1.00 X 0 0 0 VERA KRYMSKAYA BOARD MEMBER 1.00 X 0 0 0 PAUL M LIEBERMAN BOARD MEMBER 1.00 X 0 0 0 ROBERT MARCANTUONO BOARD MEMBER 1.00 X 0 0 0 JESSICA MULHOLLAND BOARD MEMBER 1.00 X 0 0 0 HOWARD M NATHAN BOARD MEMBER 1.00 X 0 0 0 LOUIS PHILIPSON BOARD MEMBER 1.00 X 0 0 0 ARTHUR H RUBENSTEIN BOARD MEMBER 1.00 X 0 0 0 JIM VAUGHT BOARD MEMBER 1.00 X 0 0 0 MICHAEL WHITE BOARD MEMBER 1.00 X 0 0 0 DEANNE TAYLOR BOARD MEMBER 1.00 X 0 0 0 ROBERT ZIPPERLEN-DEC'D 32623 VP ADMINISTRATION & CFO 37.50 X 68373 0 11588 TOM MALECKI CFO; VP, ADMINISTRATION 37.50 X 112788 0 239 THOMAS BELL CHIEF SCIENTIFIC OFFICER 37.50 X 239542 0 12482 MELISSA W VONDRAN SR VP, OPERATIONS 35.00 X 184997 0 6343 SABOOR A SHAD DIRECTOR, TISSUE SOURCE SI 37.50 X 108583 0 12918 DANA R ROSALES DIRECTOR, FULFILLMENT 37.50 X 112413 0 38345 1233897 0 148315 6 0 1 0 CONNECTLIFE (UPSTATE NEW YORK TRANSPLANT 4444 BRYANT AND STRATTON WAY WILLIAMSVILLE NY 142216013 ORGAN/TISSUE PROCUREMENT 225750 CHILDREN'S HOSPITAL OF PHILADELPHIA RESE 3401 CIVIC CENTER BLVD PHILADELPHIA PA 19104 DGTEX SUBCONTRACT SERVICES 224732 CENTER FOR ORGAN RECOVERY & EDUCATION 204 SIGMA DRIVE PITTSBURGH PA 152382825 ORGAN/TISSUE PROCUREMENT 187110 JOHNS HOPKINS UNIVERSITY 733 N BROADWAY BALTIMORE MD 21205 DGTEX AND SMAHT SUBCONTRACT SERVICES 159768 UNIVERSITY OF MARYLAND BALTIMORE 220 ARCH STREET OFFICE LEVEL 2 BALTIMORE MD 212011531 DGTEX AND SMAHT SUBCONTRACT SERVICES 137368 6 4675831 16 4675847 RESEARCHER FEES 541700 2968476 2968476 CORPORATE CONTRACTS 541700 1467261 1467261 ANCILLARY REVENUE, NET 541700 -42574 -42574 4393163 77477 77477 9146487 4393163 0 77477 625856 625856 2360080 1864728 495352 50534 27415 23119 384167 384167 222609 133565 89044 18988 18988 72099 72099 101865 101865 62526 27473 35053 723618 269180 454438 272783 272783 35790 31499 4291 156385 81572 74813 378914 378914 76608 76608 BIOMATERIAL PROCUREMENT 1200499 1200499 SUBCONTRACTORS 1125855 1125855 REMOTE SITES 559986 559986 SHIPPING AND DELIVERY 354879 354879 470831 261093 209738 9254872 6321911 2932961 0 500 500 1131037 1153774 1997642 2682185 44910 44910 107800 90852 6041967 4573824 1724260 1468143 1901966 1741447 6908115 7181811 736959 1681296 2263 0 1150596 886310 3095537 2823530 4985355 5391136 X 1922760 1790675 1922760 1790675 6908115 7181811 X -108385 -23700 X 0 1 X 1 1 1 X 1921484 1972329 2894859 3309348 4675847 14773867 1921484 1972329 2894859 3309348 4675847 14773867 14773867 11545 9666 254 15922 77477 114864 14888731 22393619 0.99230 0.99650 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 9254872 9254872 612744 153186 0 0 513261 500177 556633 612744 2182815 3274223 128315 125044 139158 153186 545703 818555 1714426 1410940 303486 4327541 3162884 1164657 1468143 OPERATING LEASE RIGHT OF USE ASSETS 1741447 1741447 OTHER NONCURRENT LIABILITIES 14987 OPERATING LEASE LIABILITY 2808543 2823530 X 9204325 57838 57838 9146487 0 9146487 9312710 57838 57838 9254872 0 9254872 PART X, LINE 2: THE INTERNAL REVENUE SERVICE HAS CLASSIFIED NDRI AS EXEMPT FROM FEDERAL INCOME TAXES UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE ("CODE"), AS AN ORGANIZATION, CONTRIBUTIONS TO WHICH ARE DEDUCTIBLE UNDER SECTION 170(C) OF THE CODE, AND AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION AS DEFINED IN SECTION 509(A) OF THE CODE. THEREFORE, NO PROVISION FOR INCOME TAXES HAS BEEN INCLUDED IN THESE FINANCIAL STATEMENTS. MANAGEMENT HAS EVALUATED THE TAX POSITIONS TAKEN BY NDRI, AND HAS CONCLUDED THAT AS OF DECEMBER 31, 2023 AND 2022, THERE ARE NO UNCERTAIN TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN THAT WOULD REQUIRE RECOGNITION OF A LIABILITY OR DISCLOSURE IN THE FINANCIAL STATEMENTS. NDRI RECOGNIZES ACCRUED INTEREST AND PENALTIES ASSOCIATED WITH UNCERTAIN TAX POSITIONS, IF ANY. THERE WERE NO INCOME TAX RELATED INTEREST OR PENALTIES RECORDED FOR EITHER OF THE YEARS ENDED DECEMBER 31, 2023 OR 2022. X X X 0 0 0 0 0 0 0 0 0 WILLIAM LEINWEBER PRESIDENT & CEO 399077 0 0 0 8124 0 13200 0 53200 0 473601 0 0 0 THOMAS BELL CHIEF SCIENTIFIC OFFICER 236167 0 0 0 3375 0 9539 0 2943 0 252024 0 0 0 MELISSA W VONDRAN SR VP, OPERATIONS 183375 0 0 0 1622 0 6104 0 239 0 191340 0 0 0 DANA R ROSALES DIRECTOR, FULFILLMENT 112413 0 0 0 0 0 4790 0 33555 0 150758 0 0 0 FORM 990, PART VI, SECTION B, LINE 11B AFTER THE FORM 990 HAS BEEN PREPARED BY THE INDEPENDENT ACCOUNTANTS, IT IS REVIEWED BY THE CFO AND THE PRESIDENT. THE FORM 990 IS THEN DISTRIBUTED TO THE BOARD OF DIRECTORS FOR REVIEW PRIOR TO SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C NDRI HAS A CONFLICT OF INTEREST POLICY FOR ALL BOARD MEMBERS AND SENIOR STAFF. ALL BOARD MEMBERS AND SENIOR STAFF ARE REQUIRED TO DISCLOSE ANY KNOWN CONFLICTS ON AN ANNUAL BASIS. FORM 990, PART VI, SECTION B, LINE 15 LETTER OF ACCOMPLISHMENTS AND RECOMMENDED INCREASE FOR THE PRESIDENT IS REVIEWED AND DECIDED UPON BY THE COMPENSATION COMMITTEE. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS AND FINANCIAL STATEMENTS ARE MADE AVAILABLE TO THE PUBLIC UPON REQUEST. FORM 990, PART XI, LINE 9: TIMING DIFFERENCE FOR PPP PROCEEDS FORGIVEN VS. RECORDED AS REVENUE CHANGE IN FAIR VALUE OF INTEREST RATE SWAP AGREEMENT -23,700.